HealthCap, Industrifonden et al. back Oncopeptides

HealthCap led the investment, with support from long-term investor Industrifonden. Members of Oncopeptides' management and board also participated in this round.

The fresh capital will be used to fund the company's phase II clinical programme, designed to enhance oncology therapies.

Company
Based in Stockhom and founded at Karolinska Institutet and Uppsala University, Oncopeptides is a clinical-stage pharmaceutical development company, working to enhance oncology therapies by creating cytosuperiors of existing basic cytotoxic compounds.

People
Jakob Lindberg is the CEO of Oncopeptides. Per Samuelsson and Johan Christenson from HealthCap have joined Oncopeptides' board of directors.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Early-stage
• Healthcare
• Now researching
• Sweden
• Industrifonden